Valuation: ImmuCell Corporation

Market Cap 9.31Cr 8.14Cr 7.48Cr 6.97Cr 13Cr 886.36Cr 13Cr 90Cr 35Cr 435.69Cr 35Cr 34Cr 1.5TCr P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 10Cr 8.96Cr 8.23Cr 7.67Cr 15Cr 975.75Cr 15Cr 99Cr 38Cr 479.63Cr 38Cr 38Cr 1.65TCr EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.43%
Yield 2024 *
-
Yield 2025 -
1 day-6.45%
1 week+4.04%
Current month+2.39%
1 month+5.11%
3 months+59.78%
6 months+73.82%
Current year+67.32%
1 week 9.68
Extreme 9.68
11.16
1 month 9.25
Extreme 9.25
11.16
Current year 5.75
Extreme 5.75
11.16
1 year 4.52
Extreme 4.52
11.16
3 years 3.34
Extreme 3.34
11.16
5 years 3.34
Extreme 3.34
11.16
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 64 15/04/2026
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Date Insider Type Main position Quantity % Market Cap.
18/06Buy

Chief Executive Officer

8,000 0.0884%
15/04Free

Director

17,899 0.1979%
15/04Other

Director

17,899 0.1979%
Change 5-day change 1-year change 3-year change Capi.($)
-6.45%+4.04%+61.03%+105.80% 9.31Cr
+1.86%+7.65%+55.77%+158.84% 1,08200Cr
+3.57%+7.42%+69.09%+58.92% 63TCr
+3.99%+7.37%+36.87%+93.77% 46TCr
-0.35%+1.85%+31.30%+24.86% 34TCr
-0.56%+2.80%+39.13%+28.20% 30TCr
-0.08%+1.52%+29.96%+42.13% 29TCr
-1.54%+3.56%-25.96%-40.53% 23TCr
+3.55%+6.05%+26.04%+68.52% 20TCr
+4.21%+6.00%+17.72%+70.33% 16TCr
Average +0.33%+5.66%+34.10%+61.08% 37TCr
Weighted average by Cap. +1.04%+5.54%+41.79%+80.53%

Financials

2024 2025
Net sales 2.65Cr 2.32Cr 2.13Cr 1.98Cr 3.76Cr 252.25Cr 3.82Cr 26Cr 9.93Cr 124Cr 9.94Cr 9.73Cr 427.28Cr 2.76Cr 2.42Cr 2.22Cr 2.07Cr 3.93Cr 263.21Cr 3.99Cr 27Cr 10Cr 129.38Cr 10Cr 10Cr 445.84Cr
Net income -21.57L -18.85L -17.33L -16.15L -30.63L -21Cr -31.1L -2.08Cr -80.86L -10Cr -80.95L -79.21L -35Cr -10.4L -9L -8L -8L -14.77L -9.9Cr -15L -1Cr -38.99L -4.87Cr -39.04L -38.2L -17Cr
Net Debt 1.13Cr 99.15L 91.12L 84.93L 1.61Cr 107.99Cr 1.64Cr 11Cr 4.25Cr 53Cr 4.26Cr 4.17Cr 182.92Cr 93.88L 82.07L 75.42L 70.3L 1.33Cr 89Cr 1.35Cr 9.05Cr 3.52Cr 44Cr 3.52Cr 3.45Cr 151.4Cr
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
02/26/02 $10.29 -6.45% 41,066
01/26/01 $11.00 +9.45% 56,155
30/26/30 $10.05 +1.41% 69,176
29/26/29 $9.910 +1.23% 21,710
26/26/26 $9.790 -1.01% 26,894
  1. Stock Market
  2. Stocks
  3. ICCC Stock